NEPH NEPHROS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1196298 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.4%
TTM net income YoY29.0%
TTM EPS YoY28.6%
Revenue 3-yr CAGR16.8%
Net income 3-yr CAGR—
Margins
Gross margin60.5%
Operating margin8.5%
Net margin8.9%
FCF margin—
EBITDA margin9.0%
Returns
ROE16.9%
ROA13.4%
ROIC (approx.)22.5%
Asset turnover1.51x
Leverage & solvency
Liabilities / assets18.0%
Debt / equity0.00x
Current ratio5.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.48x
Accruals ratio19.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $18.79M | $14.16M |
| Cost of revenue | $7.16M | $5.44M |
| Gross profit | $11.62M | $8.72M |
| R&D expense | $1.34M | $906,000 |
| SG&A expense | $9.00M | $7.68M |
| Operating income | $1.15M | $6,000 |
| Interest expense | $1,000 | $1,000 |
| Pretax income | $1.21M | $89,000 |
| Income tax | $12,000 | $15,000 |
| Net income | $1.19M | $74,000 |
| EBITDA | $1.29M | $141,000 |
| EPS (basic) | 0.11 | 0.01 |
| EPS (diluted) | 0.11 | 0.01 |
| Weighted avg. shares (diluted) | 10.97M | 10.60M |
| Balance sheet | ||
| Cash & equivalents | $5.40M | $3.76M |
| Receivables | $2.41M | $1.78M |
| Inventory | $3.23M | $2.62M |
| Current assets | $11.22M | $8.30M |
| PP&E, net | $106,000 | $161,000 |
| Goodwill | $759,000 | $759,000 |
| Intangibles | $318,000 | $349,000 |
| Total assets | $13.64M | $11.21M |
| Current liabilities | $2.77M | $1.56M |
| Total liabilities | $3.44M | $2.62M |
| Shareholders' equity | $10.20M | $8.59M |
| Shares outstanding | 10.64M | 10.54M |
| Cash flow statement | ||
| Operating cash flow | $1.65M | -$492,000 |
| Capital expenditure | — | $55,000 |
| Free cash flow | — | -$547,000 |
| Investing cash flow | $0 | -$50,000 |
| Financing cash flow | -$5,000 | -$5,000 |
| Depreciation & amortization | $140,000 | $135,000 |
| Stock-based compensation | $296,000 | $153,000 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.